Related Experiment Video

Updated: Jul 8, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Reduction of C-reactive protein and the use of anti-hypertensives

Carmine Savoia1, Ernesto L Schiffrin

  • 1Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC, Canada.

Vascular Health and Risk Management
|January 19, 2008
PubMed

Insights

Vascular inflammation plays a key role in hypertension and cardiovascular disease. Targeting inflammation, alongside blood pressure control, may improve patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Hypertension Pathophysiology

Background:

  • Inflammatory processes are critical in the development of hypertension and cardiovascular disease.
  • Angiotensin II contributes to vascular inflammation via oxidative stress and inflammatory mediator upregulation.
  • Elevated C-reactive protein levels in hypertensive patients predict cardiovascular disease and may act as a pro-inflammatory agent.

Purpose of the Study:

  • To explore the role of vascular inflammation in hypertension.
  • To investigate the combined predictive value of C-reactive protein and hypertension for cardiovascular outcomes.
  • To evaluate therapeutic strategies for reducing vascular inflammation in hypertensive individuals.

Main Methods:

  • Review of current literature on inflammation, hypertension, and cardiovascular disease.
  • Analysis of the role of Angiotensin II and C-reactive protein in vascular inflammation.
  • Examination of evidence for lifestyle modifications and pharmacological interventions.

Main Results:

  • Hypertension and elevated C-reactive protein are independent determinants of cardiovascular risk.
  • Combined elevation of blood pressure and C-reactive protein has additive predictive value for cardiovascular outcomes.
  • Therapeutic interventions targeting vascular inflammation show promise.

Conclusions:

  • Reducing vascular inflammation is a potential therapeutic target in hypertension.
  • Lifestyle modifications and pharmacological approaches, including renin-angiotensin system antagonism, may reduce blood pressure and inflammation.
  • Angiotensin receptor blockers may improve cardiovascular outcomes by mitigating vascular inflammation and remodeling, beyond blood pressure reduction.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...